We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Polarean Imaging Plc | LSE:POLX | London | Ordinary Share | GB00BF3DT583 | ORD GBP0.00037 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.90 | 3.80 | 4.00 | 3.90 | 3.90 | 3.90 | 295,776 | 08:00:04 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 1.03M | -13.91M | -0.0644 | -0.61 | 8.42M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/11/2019 16:29 | Sometime between now and mid Jan. Likely first couple weeks of jan. What’s BTFD? | rhatton | |
28/11/2019 15:41 | When are results expected? Worthy of BTFD? | cooltools | |
28/11/2019 15:17 | Not exactly great price action here in the lead up to results. | rhatton | |
15/11/2019 14:57 | This will recover eventually, comercial business model is very good. Tech is phenomenal and we have a board that's interests are aligned with shareholders, disappointed by the Fda delay but hey what can you do | superstockman | |
14/11/2019 16:36 | bad start on this stock for me delay to FDA approval etc. quickly down 25% in the blink of any eye!!!!!! | finkie | |
09/11/2019 14:11 | The company has options to generate cash next year and say a raise will not be required. Don't forget they can sell machines at $500k each c50% gross margins for research purposes and there are I believe other ways to generate cash before FDA approval and very large revenues kick in. Also burn rate will be much lower after submission. | loglorry1 | |
08/11/2019 14:11 | Inverview out on Vox, sound's like a sensible approach to request pre nda meeting to dot the i's and cross the t's given current fda trend. Process could take much quicker if fda responses are timely. | aimsurfer | |
08/11/2019 10:00 | Agreed that there is value in the company. Just annoyed that timelines have slipped. | mcfly79 | |
08/11/2019 07:42 | Wow over 22 million options and warrants outstanding on top of 114 million shares in issue on top of more confetti required next year | hamidahamida | |
07/11/2019 22:55 | They had US$1.28m cash on 30 June and raised another £2m in July. Even if they do need to raise again it won't be until second half next year and until then lots of value to be added. What's the harm with them raising another £2m at some point next year?Over $50m spent on research, key patents, successful phase III trial done, commercialisation planned. How much do you think a company at that stage of development is worth? | aimsurfer | |
07/11/2019 16:10 | Bit of a slip on timelines. I was hoping they would be on VOX today. Readout will now be mid January and NDA submission by end of Q2 2020. FDA then have up to 12 months to review. So may not have commercial orders until mid 2021. Based on that timeline they will need a fundraise before commercial launch. | mcfly79 | |
07/11/2019 14:42 | 8 months before they might get the approval long wait Big worry here now is Placing | hamidahamida | |
07/11/2019 08:32 | Eye's on the prize. Those who wanted sales tomorrow have no clue on the potential here nor the value and interest each milestone brings to the company. I hope for gradual rise over coming weeks and months. Trial results is a major milestones, and industry interest should follow. Commercialisation plans already started. Would expect collaboration agreements with majors and potentially news from EMEA and Asia. If you want to see potential here, Blue Earth Diagnostics sold for $450m. | aimsurfer | |
07/11/2019 07:35 | Another 8 months wait before they might get the FDA approval | hamidahamida | |
01/11/2019 11:51 | Trial completion any day now, results and FDA submission before year end. Few collaborations, FDA approval and initial revenue from scans in late 2020 would do me nicely :) | aimsurfer | |
01/11/2019 10:24 | new investor to this company here can someone briefly update me on key timelines here, many thanks | finkie | |
30/10/2019 09:36 | I think trials are scheduled to complete end of the monthSo news any time? | mrs robinson | |
28/10/2019 22:22 | Two large traders reported late, not sure if it was a transfer of stock. Interestingly I could sell a decent chunk all week at close the live price, there must be some buyers in the background. Anyway very close now to trial completion. | aimsurfer | |
28/10/2019 16:31 | Chunky trade just gone through! | rhatton | |
22/10/2019 16:58 | Phase 3 success and few collaborations in the bag I hope to see us around 50p, this is before official FDA approval. Bigger gains once commercial rollout begins? | aimsurfer | |
22/10/2019 16:09 | What are the projections around here if things are successful with phase 3? | rhatton | |
16/10/2019 15:18 | Two patients left, one in each trial. Will complete in October and results still expected to be announced this year.Expecting good Xmas here :) | aimsurfer | |
16/10/2019 13:53 | New podcast Listen to "Richard Hullihen CEO of Polarean Imagining and John Meyer on Resource Stocks" https://www.voxmarke | hamidahamida |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions